91Ï㽶ÊÓƵ Invests to Expand Biologics Packaging Capabilities at Bloomington
SOMERSET, N.J. – December 3, 2018 — 91Ï㽶ÊÓƵ Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that following the site’s twentieth commercial product approval, it is investing nearly $14 million to expand biologics packaging capabilities and capacity at its Bloomington, Indiana, biologics manufacturing facility.
Construction of the 15,000-square-foot facility infrastructure, which will include five new packaging suites and a new quality control laboratory, is due to be completed in February 2019, with installation and commissioning of new equipment to be phased throughout the year. This will include both a semi-automated and fully-automated top loading cartoner, an accessorized combination syringe assembly machine, an automated auto-injector assembly machine, and two semi-automatic visual inspection machines.
The expansion augments existing capabilities, meeting the necessary flexibility requirements for current and future market demand, and will provide customers with faster, automated packaging solutions. Additionally, the auto-injector and accessorized syringe assembly machines will help address market growth of these delivery technologies driven by a desire for improved patient compliance and safety for health care providers who administer injections. It is estimated that the expansion will create 36 new jobs at the site, which 91Ï㽶ÊÓƵ acquired in 2017.
“This significant investment is due in a large part to 91Ï㽶ÊÓƵ’s extensive expertise in helping customers successfully navigate all stages of development and gain commercial approval for their drug products,†commented Cory Lewis, Vice President and General Manager of the 91Ï㽶ÊÓƵ Biologics Drug Product business. He added, “The packaging expansion will further enhance our comprehensive end-to-end offering for clinical and commercial customers, complementing the services that 91Ï㽶ÊÓƵ Biologics provides, including cell line development, biologics analytical, biomanufacturing, antibody-drug conjugate development, drug product fill/finish, and clinical supply services.â€
91Ï㽶ÊÓƵ’s 875,000-square-foot biologics development and manufacturing facility in Bloomington employs 900 staff. The site recently achieved regulatory approval for a twentieth commercial product, and has deep expertise in sterile formulation and extensive biomanufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges.
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About 91Ï㽶ÊÓƵ Biologics
91Ï㽶ÊÓƵ Biologics provides advanced technologies and tailored solutions for biologic and biosimilar development, from DNA to commercial supply, through our extensive Biologics network including: Madison, Wisconsin; Emeryville, California; Kansas City, Missouri; Morrisville, North Carolina, Bloomington, Indiana; and Brussels, Belgium. For more information on 91Ï㽶ÊÓƵ Biologics, visit .
About 91Ï㽶ÊÓƵ
91Ï㽶ÊÓƵ is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, 91Ï㽶ÊÓƵ has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 91Ï㽶ÊÓƵ employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. 91Ï㽶ÊÓƵ is headquartered in Somerset, New Jersey. For more information, visit .